Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing

Xiao, Shiju; Zhang, Guangzhong; Jiang, Chunyan; Liu, Xin; Wang, Xiaoxu; Li, Yafan; Cheng, Meijiao; Lv, Hongpeng; Xian, Fuyang; Guo, Xinwei; Tan, Yong

doi:10.3389/fcimb.2021.605825

Cited by 34 publications

(12 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunological and inflammatory responses in psoriasis patients are affected by gut microbiota dysbiosis, enhanced pathways, and dysregulated metabolites [ 46 ].…”

Section: Gut Microbiome Alterations In Psoriasismentioning

confidence: 99%

Gut Microbiota in Psoriasis

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease with autoimmune pathogenic characteristics and is caused by chronic inflammation, which results in uncontrolled keratinocyte growth and defective differentiation. The link between the gut microbiota and immune system regulation opened a novel angle to understand the pathogenesis of many chronic multifactorial diseases, including psoriasis. Current evidence suggests that modulation of the gut microbiota, both through dietary approaches and through supplementation with probiotics and prebiotics, could represent a novel therapeutic approach. The present work aims to highlight the latest scientific evidence regarding the microbiome alterations of psoriatic patients, as well as state of the art insights in terms of microbiome-targeted therapies as promising preventive and therapeutic tools for psoriasis.

show abstract

“…The immunological and inflammatory responses in psoriasis patients are affected by gut microbiota dysbiosis, enhanced pathways, and dysregulated metabolites [ 46 ].…”

Section: Gut Microbiome Alterations In Psoriasismentioning

confidence: 99%

Gut Microbiota in Psoriasis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Most interestingly, the gut microbiota of psoriasis patients significantly differentially expressed 15 kyoto encyclopaedia of genes and genomes (KEGG) biosynthetic pathways. These included upregulation of lipopolysaccharide (LPS) biosynthesis, the bacterial secretion and phosphotransferase systems and fructose and mannose metabolism; and downregulation of signalling through cell surface receptors (WNT signalling), apoptosis and sulphur metabolism pathways [ 115 ]. LPS contains a potent endotoxin component (Lipid A), responsible for the septic shock caused by circulating Gram‐negative pathogens.…”

Section: Axes Of Microbial Activity and Diseasementioning

confidence: 99%

The human microbiome in disease and pathology

Manos

2022

APMIS

View full text Add to dashboard Cite

This narrative review seeks to examine the relationships between bacterial microbiomes and infectious disease. This is achieved by detailing how different human host microbiomes develop and function, from the earliest infant acquisitions of maternal and environmental species through to the full development of microbiomes by adulthood. Communication between bacterial species or communities of species within and outside of the microbiome is a factor in both maintenance of homeostasis and management of threats from the external environment. Dysbiosis of this homeostasis is key to understanding the development of disease states. Several microbiomes and the microbiota within are used as prime examples of how changes in species composition, particularly at the phylum level, leads to such diverse conditions as inflammatory bowel disease (IBD), type 2 diabetes, psoriasis, Parkinson’s disease, reflux oesophagitis and others. The review examines spatial relationships between microbiomes to understand how dysbiosis in the gut microbiome in particular can influence diseases in distant host sites via routes such as the gut–lung, gut–skin and gut–brain axes. Microbiome interaction with host processes such as adaptive immunity is increasingly identified as critical to developing the capacity of the immune system to react to pathogens. Dysbiosis of essential bacteria involved in modification of host substrates such as bile acid components can result in development of Crohn’s disease, small intestine bacterial overgrowth, hepatic cancer and obesity. Interactions between microbiomes in distantly located sites are being increasingly being identified, resulting in a ‘whole of body’ effect by the combined host microbiome.

show abstract

“…Individuals with inflammatory diseases, including BD and Crohn's disease; systematic diseases, including cardiovascular diseases, diabetes and anemia; infectious diseases; and a history of drug abuse were excluded from this study. In this study, 81 RAU patients receiving no medication consisting of antibiotics, corticosteroids or analgesics for at least 1 month along with 44 sex-, age-, and BMI-matched healthy controls were recruited according to the previous studies on gut microbiota and metagenomic analysis (46)(47)(48). Information on lifestyle, oral health status, clinical characteristics of ulcers, and blood testrelated data were obtained.…”

Section: Study Subjectsmentioning

confidence: 99%

A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide

Wang

Xiong²,

Huang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Recurrent aphthous ulcer (RAU), one of the most common diseases in humans, has an unknown etiology and is difficult to treat. Thalidomide is an important immunomodulatory and antitumor drug and its effects on the gut microbiota still remain unclear. We conducted a metagenomic sequencing study of fecal samples from a cohort of individuals with RAU, performed biochemical assays of cytokines, immunoglobulins and antimicrobial peptides in serum and saliva, and investigated the regulation effects of thalidomide administration and withdrawal. Meanwhile we constructed the corresponding prediction models. Our metagenome-wide association results indicated that gut dysbacteriosis, microbial dysfunction and immune imbalance occurred in RAU patients. Thalidomide regulated gut dysbacteriosis in a species-specific manner and had different sustainable effects on various probiotics and pathogens. A previously unknown association between gut microbiota alterations and RAU was found, and the specific roles of thalidomide in modulating the gut microbiota and immunity were determined, suggesting that RAU may be affected by targeting gut dysbacteriosis and modifying immune imbalance. In-depth insights into sophisticated networks consisting of the gut microbiota and host cells may lead to the development of emerging treatments, including prebiotics, probiotics, synbiotics, and postbiotics.

show abstract

Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing

Cited by 34 publications

References 90 publications

Gut Microbiota in Psoriasis

Gut Microbiota in Psoriasis

The human microbiome in disease and pathology

A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide

Contact Info

Product

Resources

About